INTERVENTIONAL, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY
TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS (IV) EPTINEZUMAB IN PAEDIATRIC
PATIENTS (6 TO 17 YEARS) FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE
- Registry ID
- 19357A
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- H. LUNDBECK A/S
- Start date
- 2023-09-08
- Last update
- 2023-06-23
Conditions
Related clinical trials
- A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ESCALATION
AND DOSE FINDING PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPN10200
IN THE PREVENTION OF EPISODIC OR CHRONIC MIGRAINE IN ADULTS (MERANTI)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL
WITH EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF XEOMIN® INJECTIONS
FOR THE PREVENTION OF EPISODIC MIGRAINE
- A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PARALLEL-GROUP STUDY
WITH EXTENSION PHASE TO EVALUATE THE EFFICACY AND SAFETY OF DYSPORT® FOR THE PREVENTION OF
EPISODIC MIGRAINE IN ADULT PARTICIPANTS
- A PHASE 3, MULTICENTER, 12-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ATOGEPANT FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN PEDIATRIC SUBJECTS 6 TO 17 YEARS OF AGE
- LONG TERM, OPEN LABEL (DOSE BLINDED), EXTENSION STUDY OF EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH CHRONIC OR EPISODIC MIGRAINE
- RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF FREMANEZUMAB IN PATIENTS (6 TO 17 YEARS) WITH EPISODIC MIGRAINE
View on source registry